India Glycols details TDS on FY2024-25 dividend of ₹5 per share
The announcement clarifies the tax implications and procedures for a previously recommended dividend. It does not introduce new financial results, strategic changes, or significant events that would directly impact the company's valuation or operations beyond standard compliance.
The announcement is a procedural communication detailing tax deduction at source (TDS) rules for the dividend declared. It provides necessary information for shareholders to comply with tax regulations, which is a standard corporate action.
India Glycols Limited has issued a communication regarding the deduction of Tax at Source (TDS) on the dividend for the Financial Year 2024-25. * The Board of Directors had recommended a 100% dividend for FY2024-25 on 16th May 2025. * Following the sub-division/split of equity shares from ₹10 face value to ₹5 face value, approved on 30th May 2025 and credited on 13th August 2025, the recommended dividend translates to ₹5 per equity share of ₹5 face value, subject to shareholder approval at the upcoming Annual General Meeting (AGM). * As per the Income Tax Act, 1961, as amended by the Finance Act, 2020, dividend is taxable in the hands of shareholders, requiring the company to deduct TDS. * For resident individuals, TDS will be 10% with a valid PAN, and 20% without PAN. No TDS will be deducted if the total dividend is below ₹10,000 or if Form 15G/15H is submitted and conditions are met. * For non-resident members, taxes will be withheld at 20% (plus applicable surcharge and cess). A lower rate as per Double Tax Avoidance Agreement (DTAA) may apply if required documents (e.g., Tax Residency Certificate, Form 10F) are provided. * A higher TDS rate (twice the specified rate or 5%) will apply to 'specified persons' who have not filed income tax returns for the previous year and had aggregate TDS/TCS of ₹50,000 or more. * Shareholders must submit all required documents for lower/nil TDS on or before Friday, 19th September 2025. * The company also urged shareholders to update their PAN, KYC details, and nomination details with their depositories or the Registrar and Share Transfer Agent (RTA).
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under corporate actions. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.